

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 49/00	A1	(11) International Publication Number: WO 97/29782 (43) International Publication Date: 21 August 1997 (21.08.97)
(21) International Application Number: PCT/GB97/00458 (22) International Filing Date: 19 February 1997 (19.02.97) (30) Priority Data: 9603466.5 19 February 1996 (19.02.96) GB 9611894.8 7 June 1996 (07.06.96) GB 9624919.8 29 November 1996 (29.11.96) GB (71) Applicant (for all designated States except US): NYCOMED IMAGING A/S [NO/NO]; Nycoveien 1-2, N-0401 Oslo (NO). (71) Applicant (for GB only): COCKBAIN, Julian [GB/GB]; 27 Ladbroke Road, London W11 3PD (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): SWAERD-NORDMO, Marit [NO/NO]; Nycomed Imaging a/s, Nycoveien 1-2, N-0401 Oslo (NO). GULLIKSEN, Per, Helge [NO/NO]; Nycomed Imaging a/s, Nycoveien 1-2, N-0401 Oslo (NO). BRAENDEN, Jorunn, Undheim [NO/NO]; Nycomed Imaging a/s, Nycoveien 1-2, N-0401 Oslo (NO). FAHLVIK, Anne, Kjersti [NO/NO]; Nycomed Imaging a/s, Nycoveien 1-2, N-0401 Oslo (NO).		(74) Agents: COCKBAIN, Julian et al.; Frank B. Dehn & Co., 179 Queen Victoria Street, London EC4V 4EL (GB). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: THERMALLY STABILIZED CONTRAST AGENT (57) Abstract This invention relates to a freeze-dried vesicle containing ultrasound contrast agent containing a freeze-drying stabilizer and thermally stable at temperatures in excess of 20 °C.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Thermally stabilized contrast agent

5 This invention relates to thermally stabilized freeze-dried vesicle containing ultrasound contrast agents and a process for their preparation.

 Vesicles (the term is used herein to denote unilamellar and multilamellar structures, eg. structures referred to variously as liposomes, micelles, microbubbles and micro-balloons) are frequently used as a means for delivering therapeutically or diagnostically active agents. In the field of ultrasound imaging contrast media, vesicles containing materials (herein referred to as vesicular materials) which are gaseous at body temperatures may be used as echogenic contrast agents, particularly for administration into the vasculature.

 Vesicular contrast media will generally be administered in the form of an aqueous dispersion containing a low concentration of the vesicles relative to the aqueous carrier medium. Accordingly storage and transportation of such vesicular contrast agents is made significantly more efficient if the vesicles can be stored in a dried form.

 Freeze-drying of vesicular compositions is possible and, for this, formulation excipients are generally included in the composition to aid the drying technique. Such excipients generally serve one of two functions. Bulking agents are added to increase the total solids content in order to achieve a mechanically more robust product. Stabilizers, otherwise referred to as cryoprotectants or lyoprotectants, are added to aid the formation of the glassy state produced during dehydration and to provide physical strength in the dried product. Examples of stabilizers used in this way include mannitol and glucose.

Freeze-dried vesicular ultrasound contrast agents while providing advantages for transport and storage due to the reduction in bulk relative to the aqueous ready-to-use dispersions, also provide problems since the freeze-dried product is not thermally stable in the range of ambient temperatures normally encountered during transportation and storage and as a result must be maintained, prior to secondary production, in an environment in which the temperature is maintained below ambient (eg. at 5 to 10°C).

It has now surprisingly been found that by appropriate choice of the stabilizer used for freeze-drying it is possible to produce freeze-dried vesicular ultrasound contrast agents which are thermally stable at ambient temperatures and above, and indeed at all temperatures normally encountered during transportation and storage.

The thermally stable freeze-dried product may then be stored and transported without need of temperature control of its environment and in particular may be supplied to hospitals and physicians for on site formulation into an administrable dispersion without requiring such users to have special storage facilities.

Thus viewed from one aspect the invention provides a freeze-dried vesicle containing ultrasound contrast agent containing a freeze-drying stabilizer and thermally stable at temperatures in excess of 20°C, preferably at least 22°C, especially 22°C, at least 25°C, more preferably at least 30°C and especially preferably at least 40°C, eg. up to 65°C or higher. Alternatively viewed the invention provides a freeze-dried vesicle containing ultrasound contrast agent containing a freeze-drying stabilizer and having a glass transition temperature (T_g) above 20°C, preferably 22°C, especially preferably at least 25°C, more preferably at least 30°C and especially preferably at least 40°C, eg. up to 65°C or higher.

Viewed from a further aspect the invention provides a process for the preparation of a thermally stable freeze-dried vesicle containing ultrasound contrast agent, which process comprises freeze-drying an aqueous dispersion comprising a vesicular ultrasound contrast agent and a freeze-drying stabilizer or mixture of stabilizers, characterised in that said stabilizer or mixture of stabilizers has a Tg value of at least 20°C (preferably at least 22°C, especially at least 25°C, more preferably at least 30°C and especially preferably at least 40°C, eg. up to 65°C or higher) and a Tg' value of -37°C or above (preferably above -36°C, especially preferably above -35°C, eg. -10 to -37°C).

Viewed from a still further aspect the invention provides an ultrasound contrast medium comprising an aqueous carrier medium, a freeze-drying stabilizer or mixture of stabilizers and an echogenic vesicular ultrasound contrast agent, characterised in that said stabilizer or mixture of stabilizers has a Tg value of at least 20°C, (preferably at least 22°C, especially at least 25°C, more preferably at least 30°C and especially preferably at least 40°C, eg. up to 65°C or higher) and a Tg' value of -37°C or above (preferably above -36°C, especially preferably above -35°C, eg. -10 to -37°C).

Viewed from a yet still further aspect the invention provides the use of a freeze-drying stabilizer or mixture of stabilizers having a Tg value of at least 20°C, (preferably at least 22°C, especially at least 25°C, more preferably at least 30°C and especially preferably at least 40°C, eg. up to 65°C or higher) and a Tg' value of -37°C or above (preferably above -36°C, especially preferably above -35°C, eg. -10 to -37°C) for the manufacture of a vesicle containing ultrasound contrast medium for use in diagnosis involving diagnostic ultrasound imaging.

Viewed from a further aspect the invention provides a process for the storage or transportation of a

vesicular ultrasound contrast agent, characterized in that said agent is in freeze-dried form, contains a freeze-drying stabilizer and has a glass transition temperature (Tg) of at least 20°C (preferably at least 22°C, etc.), and in that storage and transportation takes place without cooling.

Viewed from a still further aspect the invention provides a process for the preparation of a vesicle containing ultrasound contrast medium, said process comprising dispersing a freeze-dried contrast agent according to the invention in physiologically tolerable aqueous dispersion medium.

For any material, Tg is the glass transition temperature of the dried material while Tg' is the glass transition temperature of the maximally freeze-concentrated pure aqueous solution of the material.

Besides the improved thermal stability, the freeze-dried vesicular contrast agents according to the invention also surprisingly enhance the ability of the vesicles to retain the halocarbon gases and gas precursors commonly used in ultrasound contrast agents.

In the invention, the ultrasound contrast agent may be any physiologically tolerable echogenic vesicular agent, preferably however the vesicles will contain a gas or gas precursor (eg. a compound or compound mixture which is substantially in gaseous (including vapour) form at normal human body temperatures (37°C)). Any biocompatible gas, gas precursor or mixture may be employed. The gas may thus, for example, comprise air; nitrogen; oxygen; carbon dioxide; hydrogen; nitrous oxide; an inert gas such as helium, argon, xenon or krypton; a sulphur fluoride such as sulphur hexafluoride, disulphur decafluoride or trifluoromethylsulphur pentafluoride; selenium hexafluoride; an optionally halogenated silane such as tetramethylsilane; a low molecular weight hydrocarbon (e.g. containing up to 7 carbon atoms), for example an

alkane such as methane, ethane, a propane, a butane or a pentane, a cycloalkane such as cyclobutane or cyclopentane, an alkene such as propene or a butene, or an alkyne such as acetylene; an ether; a ketone; an ester; a halogenated low molecular weight hydrocarbon (e.g. containing up to 7 carbon atoms); or a mixture of any of the foregoing. At least some of the halogen atoms in halogenated gases advantageously are fluorine atoms. Thus biocompatible halogenated hydrocarbon gases may, for example, be selected from bromochlorodifluoromethane, chlorodifluoromethane, dichlorodifluoromethane, bromotrifluoromethane, chlorotrifluoromethane, chloropentafluoroethane, dichlorotetrafluoroethane and perfluorocarbons, e.g. perfluoroalkanes such as perfluoromethane, perfluoroethane, perfluoropropanes, perfluorobutanes (e.g. perfluoro-n-butane, optionally in admixture with other isomers such as perfluoro-isobutane), perfluoropentanes, perfluorohexanes and perfluoroheptanes; perfluoroalkenes such as perfluoropropene, perfluorobutenes (e.g. perfluorobut-2-ene) and perfluorobutadiene; perfluoroalkynes such as perfluorobut-2-yne; and perfluorocycloalkanes such as perfluorocyclobutane, perfluoromethylcyclobutane, perfluorodimethylcyclobutanes, perfluorotrimethylcyclobutanes, perfluorocyclopentane, perfluoromethylcyclopentane, perfluorodimethylcyclopentanes, perfluorocyclohexane, perfluoromethylcyclohexane and perfluorocycloheptane. Other halogenated gases include fluorinated, e.g. perfluorinated, ketones such as perfluoroacetone and fluorinated, e.g. perfluorinated, ethers such as perfluorodiethyl ether.

Particularly preferably, the vesicles will contain a perfluoroalkane, especially a perfluorobutane, perfluoropentane or perfluorohexane, in particular n-perfluorobutane.

In the vesicles, the membrane may be formed of any physiologically tolerable membrane forming material, in

particular phospholipids, and may be cross-linked or non-cross-linked. Membranes formed of mixtures of charged and non-charged phospholipids are especially preferred and it is particularly preferred that the vesicles should carry a net surface charge, preferably a negative charge. Such phospholipid vesicles have particularly favourable blood residence times.

The vesicles may further be provided with a blood residence prolonging agent, eg. by conjugating such an agent to the membrane or to a lipophilic group which will anchor within the membrane. Such blood residence prolonging agents, eg. polyalkylene oxides such as polyethylene glycol, can act as opsonisation inhibitors delaying the uptake of the vesicles from the vasculature by the reticuloendothelial system.

Desirably at least 75%, preferably substantially all of the phospholipid material in the contrast agents of the invention consists of molecules which individually bear a net overall charge under conditions of preparation and/or use, which charge may be positive or, more preferably, negative. Representative positively charged phospholipids include esters of phosphatidic acids such as dipalmitoylphosphatidic acid or distearoylphosphatidic acid with aminoalcohols such as hydroxyethylenediamine. Examples of negatively charged phospholipids include naturally occurring (e.g. soya bean or egg yolk derived), semisynthetic (e.g. partially or fully hydrogenated) and synthetic phosphatidylserines, phosphatidylglycerols, phosphatidylinositols, phosphatidic acids and cardiolipins. The fatty acyl groups of such phospholipids will typically each contain about 14-22 carbon atoms, for example as in palmitoyl and stearyl groups. Lyso forms of such charged phospholipids are also useful in accordance with the invention, the term "lyso" denoting phospholipids containing only one fatty acyl group, this preferably being ester-linked to the 1-

position carbon atom of the glyceryl moiety. Such lyso forms of charged phospholipids may advantageously be used in admixture with charged phospholipids containing two fatty acyl groups.

5 Phosphatidylserines represent particularly preferred phospholipids for use in contrast agents according to the invention and preferably constitute a substantial part, e.g. at least 80% of the initial phospholipid content thereof, for example 85 - 92%,
10 although this may subsequently be reduced somewhat, e.g. to ca. 70%, in subsequent processing such as heat sterilisation. While we do not wish to be bound by theoretical considerations, it may be that ionic bridging between the carboxyl and amino groups of
15 adjacent serine moieties contributes to the stability of such systems. Preferred phosphatidylserines include saturated (e.g. hydrogenated or synthetic) natural phosphatidylserine and synthetic or semisynthetic dialkanoylphosphatidylserines such as distearoyl-
20 phosphatidylserine, dipalmitoylphosphatidylserine and diarachidoylphosphatidylserine.

 An important advantage of the use of such phosphatidylserine-based contrast agents is that the body recognises aged red blood cells and platelets by
25 high concentrations of phosphatidylserine on their surface and so may eliminate such contrast agents from the blood stream in a manner similar to the elimination of aged red blood cells. Furthermore, since the surface of such contrast agents may be registered as endogenous
30 by the body, they may avoid induction of adverse systemic side effects such as haemodynamic effects and other anaphylactic reactions which may accompany administration of some liposome preparations (see e.g. WO-A-95/12386).

35 Liposomal ultrasound contrast agents suitable for use according to the invention may be prepared as described in the literature, see for example WO-A-92/

22247, WO-A-94/28780, WO-A-93/05819, WO-A-95/16467, PCT/GB96/01361 and Unger et al. Invest. Radiol. 29 (Suppl. 2): S134-S136 (1994).

5 The stabilizer used according to the invention may be a physiologically tolerable freeze-drying stabilizer (or mixture) having a glass transition temperature (T_g) above 20°C, eg. in the range 25 to 70°C, and having a T_g value of -37°C or above. Examples of suitable stabilizers include sucrose, maltose H_2O , trehalose, 10 raffinose and stachyose. One particularly suitable example is sucrose, optionally in admixture with minor quantities (eg. up to 20% by weight, preferably up to 10% by weight) of other stabilizers.

15 In general the stabilizer will be present in the composition being freeze-dried at a concentration significantly in excess of that of the vesicular contrast agent, eg. at a weight ratio of at least 10:1, more normally at least 20:1, optimally as high as 200:1, eg. up to 5000:1 or even higher. Accordingly, the 20 contribution to the glass transition temperature (T_g) of the dried product is relatively independent of the vesicular component and candidate stabilizers can be screened easily by routine techniques to determine whether they, in combination with the other excipients 25 present in the aqueous carrier medium, dry to form a product having a glass transition temperature (T_g) above 20°C.

Conveniently the stabilizer will be present at 1 to 50% by weight, preferably 5 to 30%, more especially 30 about 10 to 20% by weight, in the composition undergoing freeze-drying. The concentration of stabilizer may if desired be well in excess of isotonic concentrations since, on reconstitution after freeze-drying, the product can be diluted. The vesicle component will 35 preferably be present at 0.01 to 5% by weight, preferably 0.1 to 3%, especially preferably about 0.5 to 1.5% by weight (considering its weight to be only the

weight of the membrane forming material). The quantity of stabilizer relative to the reconstitution fluid used to transform the freeze-dried product into an administrable dispersion will be selected dependent on the body region or organ to be imaged and on the administration mode chosen. By way of example it may be at least twice that in the composition which underwent freeze-drying.

For ultrasound applications such as echocardiography, in order to permit free passage through the pulmonary system and to achieve resonance with the preferred imaging frequencies of about 0.1-15 MHz, it may be convenient to employ vesicles having an average size of 0.1-10 μm , e.g. 1-7 μm . The vesicles may be produced with a very narrow size distribution within the range preferred for echocardiography, thereby greatly enhancing their echogenicity as well as their safety in vivo, and rendering the contrast agents of particular advantage in applications such as blood pressure measurements, blood flow tracing and ultrasound tomography. Thus, for example, products in which over 90% (e.g. at least 95%, preferably at least 98%) of the vesicles have diameters in the range 1-7 μm and less than 5% (e.g. not more than 3%, preferably not more than 2%) of the vesicles have diameters above 7 μm may readily be prepared.

In ultrasound applications the contrast media may, for example, be administered in doses such that the amount of membrane forming material (eg. phospholipid) injected is in the range 0.1-10 $\mu\text{g/kg}$ body weight, more preferably 1-5 $\mu\text{g/kg}$. It will be appreciated that the use of such low levels of membrane forming material is of substantial advantage in minimising possible toxic side effects.

The overall membrane forming material concentration in ready-to-use compositions made using the dried product of the invention will desirably be in the range

0.01 to 5% by weight, preferably 0.05 to 2.0% and particularly about 0.5% by weight.

The composition subjected to freeze-drying will advantageously contain at least one bulking agent, eg. a
5 polyol (eg. a C₃ polyol such as glycerol or propylene glycol) or a polysaccharide such as dextran, or a polyglycol such as polyethylene glycol or mixtures thereof. Typically the bulking agent may be used in concentrations similar to or slightly less than that of
10 the stabilizer, eg. 3 to 10% by weight, preferably about 5% by weight. The bulking agents should be able to crystallize during the freeze-drying process as only in this state do they have a neutral effect on product stability. They are thus distinguished from the
15 stabilizers which should be present in the amorphous state during freeze-drying.

Other excipients may if desired be present in the composition being dried or may be added on formulation for administration. Such excipients may for example
20 include pH regulators, osmolality adjusters, viscosity enhancers, emulsifiers, etc. and may be used in conventional amounts.

The dried product will generally be in powder form and is readily reconstitutable in water, an aqueous
25 solution such as saline (which may advantageously be balanced so that the final product for injection is not hypotonic), or a solution of one or more tonicity adjusting substances such as salts (eg. of plasma cations with physiologically tolerable counterions), or
30 sugars, sugar alcohols, glycols and other non-ionic polyol materials (eg. glucose, sucrose, sorbitol, mannitol, glycerol, polyethylene glycols, propylene glycols and the like). Reconstitution will generally require only minimal agitation such as may, for example,
35 be provided by gentle hand-shaking. The size of the vesicles so generated is consistently reproducible and in practice is independent of the amount of agitational

energy applied, being determined by the size of the vesicles formed in the initial vesicle dispersion, this size parameter surprisingly being substantially maintained in the lyophilised and reconstituted product.

5 Thus, since the size of the vesicles in the initial dispersion may readily be controlled by process parameters such as the method, speed and duration of agitation, the final vesicle size may readily be controlled.

10 The volume and concentrations of the reconstitution liquid may desirably be balanced to make the resulting ready-to-use formulations substantially isotonic. Hence the volume and concentration of reconstitution fluid chosen will be dependent on the type and amount of

15 stabilizer (and other bulking agents) present in the freeze-dried product.

Lyophilised products according to the invention have proved to be storage stable for several months under ambient conditions. The vesicle dispersions

20 generated upon reconstitution in water (or other reconstitution liquids as discussed above) may be stable for considerable lengths of time, eg. up to at least 12 hours, permitting considerable flexibility as to when the dried product is reconstituted prior to injection.

25 If the reconstitution liquid contains as a tonicity adjuster the same compound as is used as a stabilizer in the lyophilization, the amount of stabilizer present in the composition for freeze-drying need only be sufficient to give the optimal stabilization during

30 freeze-drying. Isotonicity of the final product may thus be obtained by selecting an adequate amount and concentration of the reconstitution liquid. Hence a considerable flexibility is permitted as to the concentration and type of compound(s) to be used as

35 stabilizer(s) during the freeze-drying step, and concentration and type of compound(s) in the reconstitution liquid, while still achieving a stable

reconstituted product.

Freeze-drying according to the invention may be effected in a conventional manner although using stabilizers according to the invention may have the added advantage that, since the compositions before drying generally have higher glass temperatures (T_g) than equivalent compositions containing cryoprotectants such as glucose or mannitol, shorter freeze-drying cycles may be used.

The invention has been described above with reference to vesicular ultrasound contrast agents. However it is also applicable to vesicular contrast agents for other diagnostic imaging modalities (eg. MRI, X-ray, SPECT, PET, magnetographic imaging etc.).

The invention will now be described further with reference to the following non-limiting Examples:

EXAMPLE 1

Preparation of lyophilized product

500.4 mg hydrogenated egg phosphatidylserine was added to 100 ml water containing 5.4% (w/w) of a mixture of propylene glycol and glycerol (3:10 w/w). The mixture was shaken and heated to 80°C for five minutes, allowed to cool to room temperature, shaken again and left standing overnight prior to use.

50 ml of the resulting solution was transferred to a round-bottomed flask with a conical neck. The flask was fitted with a glass jacket having a temperature control inlet and outlet connected to a water bath maintained at 25°C. A rotor stator mixing shaft was introduced into the solution and to avoid gas leakage the space between the neck wall and the mixing shaft was sealed with a specially designed metal plug fitted with a gas inlet/ outlet connection for adjustment of gas content and pressure control. The gas outlet was

connected to a vacuum pump and the solution was degassed for one minute. An atmosphere of perfluoro-n-butane gas was then applied through the gas inlet.

5 The solution was homogenised at 23000 rpm for 10 minutes, keeping the rotor stator mixing shaft such that the openings were slightly above the surface of the liquid. A white coloured creamy dispersion was obtained, which was transferred to a sealable container and flushed with perfluoro-n-butane. The dispersion was
10 then transferred to a separating funnel and centrifuged at 12000 rpm for 30 minutes, yielding a creamy layer of bubbles at the top and a turbid infranatant. The infranatant was removed and replaced with water. The centrifugation was then repeated twice, but now at 12000
15 rpm for 15 minutes. After the last centrifugation, the supernatant was replaced by 10 % (w/w) sucrose. 2 ml portions of the resulting dispersion were divided between 10 ml flat-bottomed vials specially designed for lyophilisation, and the vials were cooled to -47°C and
20 lyophilised for approximately 48 hours, giving a white fluffy solid substance. The vials were transferred to a vacuum chamber, and air was removed by a vacuum pump and replaced by perfluoro-n-butane gas. Prior to use, water was added and the vials were gently hand-shaken for
25 several seconds, giving microbubble dispersions suitable as ultrasound contrast agents.

Characterisation

30 The size distribution and volume concentration of the microbubbles were measured using a Coulter Counter Mark II apparatus fitted with a 50 μm aperture with a measuring range of 1-30 μm . 20 μl samples were diluted in 200 ml saline saturated with air at room temperature,
35 and allowed to equilibrate for 3 minutes prior to measurement.

Ultrasound characterisation was performed on a

experimental set up slightly modified from de Jong, N. and Hoff, Ultrasonics, 31: 175-181 (1993). This instrumentation measures the ultrasound attenuation efficacy in the frequency range 2-8 MHz of a dilute suspension of contrast agent. During the attenuation measurement a pressure stability test was performed by exposing the sample to an overpressure of 120 mmHg for 90 seconds. Typically 2-3 μ l of sample was diluted in 55 ml Isoton II and the diluted sample suspension was stirred for 3 minutes prior to analysis. As primary response parameter the attenuation at 3.5 MHz was used, together with the recovery attenuation value at 3.5 MHz after release of the overpressure.

Table 1

In vitro characteristics of bubble dispersions produced according to Example 1. Number and volume weighted concentrations and volume mean diameters. Acoustic properties measured according to description above.

Number conc. [10 ⁶ / ml]	Vol. conc [%]	Vol. mean diam. [μ m]	Atten. at 3.5Mhz [dB/cm]	Survival after over- pressure [%]	Freq. at max. atten. [MHz]
10518	6.51	3.16	150.4	96	4.3

EXAMPLE 2

The gas contents of five samples prepared according to Example 1 above were replaced with air, perfluorobutane, sulphur hexafluoride, trifluoromethylsulphur pentafluoride and tetramethylsilane respectively, according to the following procedure:

Two samples containing lyophilised product from Example 1 were placed in a desiccator having a gas inlet and a gas outlet. The desiccator was connected to a

Büchi 168 vacuum/distiller controller which permitted controlled evacuation of the samples and inlet of a selected gas. The samples were evacuated at approximately 10 mbar for 5 minutes, whereafter the pressure was increased to atmospheric by inlet of the selected gas, followed by careful capping of the vials. The procedure was repeated using further pairs of samples for each of the selected gases.

2 ml distilled water was added to each vial and the vials were gently hand-shaken prior to use. The resulting microbubble dispersions were characterised with respect to size distribution measurements as described in Example 1. The results are summarised in Table 2.

Table 2

In vitro characteristics of phosphatidylserine-stabilised microbubble dispersions produced according to Example 2 - number and volume weighted concentrations and volume mean diameters.

Gas	Number conc. [10 ⁶ /ml]	Number mean diam. [μm]	Vol. conc. [%]	Vol. mean diam. [μm]
Perfluorobutane	9756	1.8	4.9	5.8
Trifluoromethyl- sulphur pentafluoride	10243	1.9	5.9	3.5
Sulphur hexafluoride	9927	1.9	5.7	3.2
Tetramethylsilane	9947	1.9	6.1	3.7
Air	9909	1.9	6.4	4.0

As will be seen from the above results there is no significant change in size distribution upon gas exchange, demonstrating that the preformed microbubble size is substantially preserved during both

lyophilisation and reconstitution.

In vivo results

5 One batch prepared with each of the five gases was
evaluated *in vivo* for Doppler enhancement properties at
10 MHz. The dispersions were injected into chinchilla
rabbits via an ear vein and measured using a Doppler
10 technique where an ultrasound probe is placed directly
on a carotid artery. Signal intensities and duration
were recorded and the integral of the Doppler curve is
calculated. The results obtained (see Table 3 below)
show that microbubbles containing perfluorobutane give
the strongest Doppler intensity enhancement.
15 Microbubbles containing sulphur hexafluoride,
trifluoromethylsulphur pentafluoride or
tetramethylsilane are only slightly less efficacious as
Doppler enhancers than those containing perfluorobutane,
giving integrals in the range 60-80% of the figure for
20 perfluorobutane.

Table 3

Results for i.v. injections of Example 2 products into
rabbits. The values are adjusted for drift in baseline.
25 The Doppler unit is defined as the increase in Doppler
signal relative to that of blood.

Gas	Integrated Arterial Doppler Enhancement (NDU.s)
Perfluorobutane*	10361
Trifluoromethylsulphur pentafluoride	8006
Tetramethylsilane	6370
Sulphur hexafluoride	6297
Air	1024

35 * Average of two injections

EXAMPLE 3

5 A vial containing lyophilised material under an atmosphere of perfluorobutane was prepared as described in Example 1. Water was added to the vial just before use to give a microbubble suspension.

200 ml Isoton II fluid was exposed to air for several days at room temperature to give a fully air-saturated solution. Another 200 ml of the fluid was
10 degassed in a vacuum flask at 60°C for one hour and cooled to room temperature while maintaining the vacuum. Air was admitted to the flask immediately prior to use.

10 μ l portions of the microbubble suspension were added to each of the fluids and the resulting mixtures
15 was incubated for 5 minutes prior to size characterisation (Coulter Multisizer Mark II).

In the degassed environment, where no diffusion of gases from the fluid into the microbubbles was expected, the mean microbubble diameter was 1.77 μ m and 0.25% of
20 the microbubbles are larger than 5 μ m. In the air-saturated fluid the corresponding values were 2.43 μ m and 0.67%; repeated measurements made after a further 5 minutes indicate that the microbubble sizes had reached a stable value.

25 These findings show that the average diameter of the microbubbles increases by only 37% when they are exposed to an air-saturated fluid analogous to arterial blood, with very few microbubbles reaching a size which might cause blockage of capillary blood vessels. This
30 may be contrasted with the doubling in size of air/perfluorohexane-containing microbubbles in a similar environment (i.e. a highly diluted dispersion of microbubbles in water containing dissolved air) reported in Example II of WO-A-95/03835.

EXAMPLE 4Comparison

5 Example 1 was repeated replacing the supernatant before lyophilization instead with (a) 65 mg/mL sucrose plus 65 mg/mL mannitol, (b) 100 mg/mL mannitol plus 50 mg/mL glucose, (c) 20 mg/mL sucrose, 76 mg/mL mannitol and 38 mg/mL glucose, and (d) 90 mg/mL sucrose.

10 The Tg' and Tg values of the wet and dried compositions were determined and are set out in Table 4 below.

Table 4

15

Formulation	Tg'	Tg
(a)	-38°C	19°C
(b)	-43°C	14°C
(c)	-42°C	12°C
(d)	-32°C	66°C

20

Formulations (a) to (c) need longer freeze-drying cycles than formulation (d) and unlike formulation (d) must be stored below ambient temperature to maintain their integrity.

25

EXAMPLE 5Gas retention

30

Material produced analogously to Example 1 but using (a) 10% (w/w) sucrose, (b) 5% (w/w) PEG 3000, (c) 2% (w/w) mannitol and 1% (w/w) glucose, and (d) 5% (w/w) trehalose to replace the supernatant prior to lyophilization was exposed to extensive flushing with N₂, exposure to repeated vacuum cycles, and crushing to test the ability of the product to retain perfluorobutane.

35

After stress treatment the remaining perfluorobutane content was determined. The results are set out in Table 5 below.

5 Table 5

10

Cryoprotectant	mg PFB/g product
Sucrose	0.69 ± 0.10
PEG 3000	≤ 0.05
Mannitol + glucose	0.29 ± 0.10
Trehalose	1.24 ± 0.38

15

In the foregoing examples, higher percentages of stabilizer (eg. 20% rather than 10%) may be used and other reconstitution fluids than water, eg. the saline or polyol solutions referred to above may be used. Similarly, the portions that are lyophilized may be larger (eg. 4mL rather than 2mL), lyophilization vials
20 may be larger (eg. 20 mL) and lyophilization may be longer (eg. 60 hours).

Claims:

1. A freeze-dried vesicle containing ultrasound contrast agent containing a freeze-drying stabilizer and thermally stable at temperatures in excess of 20°C.
5
2. A freeze-dried vesicle containing ultrasound contrast agent containing a freeze-drying stabilizer and having a glass transition temperature (Tg) above 20°C.
10
3. A contrast agent as claimed in either of claims 1 and 2 wherein said stabilizer is selected from the group consisting of sucrose, maltose.H₂O, trehalose, raffinose and stachyose.
15
4. A contrast agent as claimed in either of claims 1 and 2 wherein said stabilizer comprises sucrose.
5. A contrast agent as claimed in any one of claims 1 to 4 wherein the weight ratio of said stabilizer to the vesicles in said agent is at least 10:1.
20
6. A contrast agent as claimed in any one of claims 1 to 4 wherein the weight ratio of said stabilizer to the vesicles in said agent is at least 20:1.
25
7. A contrast agent as claimed in any one of claims 1 to 6 wherein the vesicles in said agent contain a halocarbon gas or gas precursor.
30
8. A contrast agent as claimed in claim 7 wherein the vesicles in said agent contain a perfluoroalkane.
9. A contrast agent as claimed in claim 7 wherein the vesicles in said agent contain a perfluoroalkane selected from perfluorobutane and perfluoropentane.
35

10. A contrast agent as claimed in any one of claims 1 to 9 wherein the membrane of the vesicles in said agent comprises a phospholipid.

5 11. A process for the preparation of a thermally stable freeze-dried vesicle containing ultrasound contrast agent, which process comprises freeze-drying an aqueous dispersion comprising a vesicular ultrasound contrast agent and a freeze-drying stabilizer or mixture of
10 stabilizers, characterised in that said stabilizer or mixture of stabilizers has a Tg value of at least 20°C and a Tg' value of -37°C or above.

12. A process as claimed in claim 11 wherein said
15 aqueous dispersion contains from 1 to 50% by weight of said stabilizer.

13. A process as claimed in either of claims 11 and 12 wherein said aqueous dispersion contains said stabilizer
20 and vesicular ultrasound contrast agent in a weight ratio of at least 10:1.

14. A process as claimed in any one of claims 11 to 13 wherein said vesicular contrast agent contains a
25 halocarbon gas or gas precursor.

15. A process as claimed in claim 14 wherein said vesicles contain a halocarbon selected from perfluorobutane and perfluoropentane.
30

16. A process as claimed in any one of claims 11 to 15 wherein said aqueous dispersion further contains a bulking agent.

35 17. A process as claimed in claim 16 wherein said bulking agent is a C₃ polyol.

- 22 -

18. A process as claimed in either of claims 16 and 17 wherein said aqueous dispersion contains 3 to 10% by weight of said bulking agent.

5 19. An ultrasound contrast medium comprising an aqueous carrier medium, a freeze-drying stabilizer or mixture of stabilizers and an echogenic vesicular ultrasound contrast agent, characterised in that said stabilizer or mixture of stabilizers has a Tg value of at least 20°C
10 and a Tg' value of -37°C or above.

20. The use of a freeze-drying stabilizer or mixture of stabilizers having a Tg value of at least 20°C and a Tg' value of -37°C or above, for the manufacture of a
15 vesicle containing ultrasound contrast medium for use in diagnosis involving diagnostic ultrasound imaging.

21. A process for the storage or transportation of a vesicle containing ultrasound contrast agent,
20 characterized in that said agent is in freeze-dried form, contains a freeze-drying stabilizer and has a glass transition temperature (Tg) of at least 20°C, and in that storage and transportation takes place without the use of cooling.

25 22. A process for the preparation of a vesicle containing ultrasound contrast medium, said process comprising dispersing a freeze-dried contrast agent as claimed in any one of claims 1 to 10 in a
30 physiologically tolerable aqueous dispersion medium.

INTERNATIONAL SEARCH REPORT

Intern: al Application No
PCT/GB 97/00458

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A61K49/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4 642 903 A (DAVIES J DESMOND) 17 February 1987 see claims 1,4,7 ---	1-22
X	US 4 857 319 A (CROWE JOHN H ET AL) 15 August 1989	1-6, 10-13, 19-22
Y	see column 2, line 23 - line 32 see column 5, line 6 - line 11 ---	1-22
A	DATABASE WPI Section Ch, Week 9435 Derwent Publications Ltd., London, GB; Class B05, AN 94-283250 XP002032806 & JP 06 211 645 A (MITSUBISHI KASEI CORP) , 2 August 1994 see abstract -----	1
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 11 June 1997		Date of mailing of the international search report 30.06.97
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016		Authorized officer Berte, M

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. al Application No

PCT/GB 97/00458

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4642903 A	17-02-87	WO 8804551 A	30-06-88
		AU 614926 B	19-09-91
		AU 6739487 A	15-07-88
		EP 0295242 A	21-12-88
		JP 2527776 B	28-08-96
		JP 1501704 T	15-06-89

US 4857319 A	15-08-89	AU 587600 B	24-08-89
		AU 5318386 A	29-07-86
		CA 1275248 A	16-10-90
		EP 0208764 A	21-01-87
		JP 62501631 T	02-07-87
		WO 8603938 A	17-07-86
